A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

• Status: Completed
• Trial end date: 2004-09-19
• Target enrollment: 0
• Participant gender: All

Summary

A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Naproxen; Rofecoxib

Criteria

Inclusion Criteria:

• Chinese males or females at least 18 years of age with rheumatoid arthritis